NCT02916160View on ClinicalTrials.gov

Sacubitril-valsartan and Heart Failure Patients : the ENTRESTO-SAS Study

PHASE4CompletedINTERVENTIONAL
Enrollment

124

Participants

Timeline

Start Date

September 22, 2016

Primary Completion Date

February 27, 2020

Study Completion Date

February 27, 2020

Conditions
Chronic Heart FailureSleep Apnea Syndrome
Interventions
DRUG

SACUBITRIL - VALSARTAN (formerly LCZ696, ENTRESTO®)

SACUBITRIL - VALSARTAN (formerly LCZ696, ENTRESTO®) is a new treatment of HF recently indicated class I, level B in the recent ESC guidelines 2016 on HF. It combines inhibitory prodrug neprilysin and valsartan.

Trial Locations (6)

30029

CHU Nimes, Nîmes

31059

CHU Toulouse, Toulouse

33604

CHU Bordeaux, Bordeaux

34295

Centre Hospitalier Universitaire de Montpellier, Montpellier

34500

Pôle médical spécialisé MSP, Béziers

34525

CHU Béziers, Béziers

All Listed Sponsors
lead

University Hospital, Montpellier

OTHER

NCT02916160 - Sacubitril-valsartan and Heart Failure Patients : the ENTRESTO-SAS Study | Biotech Hunter | Biotech Hunter